Alexandre Carpentier

Alexandre Carpentier

Auto-generated profile, based on publicly available information

Alexandre Carpentier

Sorbonne Université, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurochirurgie, Paris, France

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2016 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
ACAlexandre Carpentier
Alexandre Carpentier
MCMichael Canney
Michael Canney
AVAlexandre Vignot
Alexandre Vignot
VRVincent Reina
Vincent Reina
KBKevin Beccaria
Kevin Beccaria
Ahmed IdbaihAhmed Idbaih
Ahmed Idbaih
An implantable ultrasound device safely disrupts the blood-brain barrier in glioblastoma patients.

1 July 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
AIAhmed Idbaih
Ahmed Idbaih
MCMichael Canney
Michael Canney
LBLisa Belin
Lisa Belin
CDCarole Desseaux
Carole Desseaux
AVAlexandre Vignot
Alexandre Vignot
ACAlexandre Carpentier
Alexandre Carpentier
Purpose: The blood-brain barrier (BBB) limits the efficacy of drug therapies for glioblastoma (GBM). Pre-clinical data indicate that low-intensity pulsed ultrasound (LIPU) can transiently disrupt the BBB and increase intracerebral drug concentrations. Experimental Design: A first-in-man, single-arm, single-center trial (NCT02253212) was initiated to investigate the transient disruption of the BBB in patients with recurrent glioblastoma (rGBM). Patients were implanted with a 1 MHz, 11.5-mm diameter cranial ultrasound device (SonoCloud-1, CarThera, Paris, France). The device was activated monthly to transiently disrupt the BBB before intravenous (IV) carboplatin chemotherapy. Results: Between 2014 and 2016, 21 patients were registered for the study and implanted with the SonoCloud-1; 19 patients received at least one sonication. In 65 US sessions, BBB disruption was visible on T1w MRI for 52 sonications. Treatment-related adverse events observed were transient and manageable: a transient edema at H1 and at D15. No carboplatin-related neurotoxicity was observed. Patients with no or poor BBB disruption (n=8) visible on MRI had a median progression-free survival (PFS) of 2.73 months, and a median overall survival (OS) of 8.64 months. Patients with clear BBB disruption (n=11) had a median PFS of 4.11 months, and a median OS of 12.94 months. Conclusions:SonoCloud-1 treatments were well tolerated and may increase the effectiveness of systemic drug therapies, such as carboplatin, in the brain without inducing neurotoxicity.

23 February 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
ACAlexandre Carpentier
Alexandre Carpentier
RSRoger Stupp
Roger Stupp
ASAdam M. Sonabend
Adam M. Sonabend
HDHenry Dufour
Henry Dufour
OCOlivier Chinot
Olivier Chinot
AIAhmed Idbaih
Ahmed Idbaih
Here, the results of a phase 1/2 single-arm trial (NCT03744026) assessing the safety and efficacy of blood-brain barrier (BBB) disruption with an implantable ultrasound system in recurrent glioblastoma patients receiving carboplatin are reported. A nine-emitter ultrasound implant was placed at the end of tumor resection replacing the bone flap. After surgery, activation to disrupt the BBB was performed every four weeks either before or after carboplatin infusion. The primary objective of the Phase 1 was to evaluate the safety of escalating numbers of ultrasound emitters using a standard 3 + 3 dose escalation. The primary objective of the Phase 2 was to evaluate the efficacy of BBB opening using magnetic resonance imaging (MRI). The secondary objectives included safety and clinical efficacy. Thirty-three patients received a total of 90 monthly sonications with carboplatin administration and up to nine emitters activated without observed DLT. Grade 3 procedure-related adverse events consisted of pre syncope (n = 3), fatigue (n = 1), wound infection (n = 2), and pain at time of device connection (n = 7). BBB opening endpoint was met with 90% of emitters showing BBB disruption on MRI after sonication. In the 12 patients who received carboplatin just prior to sonication, the progression-free survival was 3.1 months, the 1-year overall survival rate was 58% and median overall survival was 14.0 months from surgery.

24 May 2021 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ASAria Sabbagh
Aria Sabbagh
KBKevin Beccaria
Kevin Beccaria
XLXiaoyang Ling
Xiaoyang Ling
AMAnantha Marisetty
Anantha Marisetty
MOMartina Ott
Martina Ott
Amy B. HeimbergerAmy B. Heimberger
Amy B. Heimberger
Purpose: The blood–brain barrier (BBB) inhibits adequate dosing/penetration of therapeutic agents to malignancies in the brain. Low-intensity pulsed ultrasound (LIPU) is a safe therapeutic method of temporary BBB disruption (BBBD) to enhance chemotherapeutic delivery to the tumor and surrounding brain parenchyma for treatment of glioblastoma. Experimental Design: We investigated if LIPU could enhance therapeutic efficacy of anti–PD-1 in C57BL/6 mice bearing intracranial GL261 gliomas, epidermal growth factor receptor variant III (EGFRvIII) chimeric antigen receptor (CAR) T cells in NSG mice with EGFRvIII-U87 gliomas, and a genetically engineered antigen-presenting cell (APC)-based therapy producing the T-cell attracting chemokine CXCL10 in the GL261-bearing mice. Results: Mice treated with anti–PD-1 and LIPU-induced BBBD had a median survival duration of 58 days compared with 39 days for mice treated with anti–PD-1, and long-term survivors all remained alive after contralateral hemisphere rechallenge. CAR T-cell administration with LIPU-induced BBBD resulted in significant increases in CAR T-cell delivery to the CNS after 24 (P < 0.005) and 72 (P < 0.001) hours and increased median survival by greater than 129%, in comparison with CAR T cells alone. Local deposition of CXCL10-secreting APCs in the glioma microenvironment with LIPU enhanced T-cell glioma infiltration during the therapeutic window (P = 0.004) and markedly enhanced survival (P < 0.05). Conclusions: LIPU increases immune therapeutic delivery to the tumor microenvironment with an associated increase in survival and is an emerging technique for enhancing novel therapies in the brain.

1 April 2017 in Journal of Neurosurgery
Verified
Journal Article
Closed access
CHCatherine Horodyckid
Catherine Horodyckid
MCMichael Canney
Michael Canney
AVAlexandre Vignot
Alexandre Vignot
RBRaphael Boisgard
Raphael Boisgard
ADAurélie Drier
Aurélie Drier
ACAlexandre Carpentier
Alexandre Carpentier
OBJECTIVE: The main limitation to the efficacy of chemotherapy for brain tumors is the restricted access to the brain because of the limited permeability of the blood-brain barrier (BBB). Previous animal studies have shown that the application of pulsed ultrasound (US), in combination with the intravenous injection of microbubbles, can temporarily disrupt the BBB to deliver drugs that normally cannot reach brain tissue. Although many previous studies have been performed with external focused US transducers, the device described in the current work emits US energy using an unfocused transducer implanted in the skull thickness. This method avoids distortion of the US energy by the skull bone and allows for simple, repetitive, and broad disruption of the BBB without the need for MRI monitoring. The purpose of the present study was to determine if the BBB can be safely and repeatedly disrupted using such an implantable unfocused US device in a primate model. METHODS: An 11.5-mm-diameter, 1-MHz, planar US device was implanted via a bur hole into the skull of 3 primates (2 Papio anubis [olive] baboons and 1 Macaca fascicularis [macaque]) for 4 months. Pulsed US sonications were applied together with the simultaneous intravenous injection of sulfur hexafluoride microbubbles (SonoVue) every 2 weeks to temporarily disrupt the BBB. In each primate, a total of 7 sonications were performed with a 23.2-msec burst length (25,000 cycles) and a 1-Hz pulse repetition frequency at acoustic pressure levels of 0.6–0.8 MPa. Potential toxicity induced by repeated BBB opening was analyzed using MRI, PET, electroencephalography (EEG), somatosensory evoked potential (SSEP) monitoring, behavioral scales, and histopathological analysis. RESULTS: The T1-weighted contrast-enhanced MR images acquired after each sonication exhibited a zone of hypersignal underneath the transducer that persisted for more than 4 hours, indicating a broad region of BBB opening in the acoustic field of the implant. Positron emission tomography images with fluorine-18–labeled fluorodeoxyglucose (FDG) did not indicate any changes in the cerebral metabolism of glucose. Neither epileptic signs nor pathological central nerve conduction was observed on EEG and SSEP recordings, respectively. Behavior in all animals remained normal. Histological analysis showed no hemorrhagic processes, no petechia, and extravasation of only a few erythrocytes. CONCLUSIONS: The studies performed confirm that an implantable, 1-MHz US device can be used to repeatedly open the BBB broadly in a large-animal model without inducing any acute, subacute, or chronic lesions.

1 March 2017 in European Journal of Cancer
Verified
Journal Article
Closed access
RURenata Ursu
Renata Ursu
ACAlexandre Carpentier
Alexandre Carpentier
PMPhilippe Metellus
Philippe Metellus
VLVincent Lubrano
Vincent Lubrano
FLFlorence Laigle-Donadey
Florence Laigle-Donadey
ACAntoine F. Carpentier
Antoine F. Carpentier